| Product NDC: | 65862-431 |
| Proprietary Name: | Ranitidine |
| Non Proprietary Name: | Ranitidine Hydrochloride |
| Active Ingredient(s): | 15 mg/mL & nbsp; Ranitidine Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SYRUP |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 65862-431 |
| Labeler Name: | Aurobindo Pharma Limited |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA090623 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100728 |
| Package NDC: | 65862-431-74 |
| Package Description: | 474 mL in 1 BOTTLE (65862-431-74) |
| NDC Code | 65862-431-74 |
| Proprietary Name | Ranitidine |
| Package Description | 474 mL in 1 BOTTLE (65862-431-74) |
| Product NDC | 65862-431 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Ranitidine Hydrochloride |
| Dosage Form Name | SYRUP |
| Route Name | ORAL |
| Start Marketing Date | 20100728 |
| Marketing Category Name | ANDA |
| Labeler Name | Aurobindo Pharma Limited |
| Substance Name | RANITIDINE HYDROCHLORIDE |
| Strength Number | 15 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Histamine H2 Receptor Antagonists [MoA],Histamine-2 Receptor Antagonist [EPC] |